Skip to Content

Of Mice and Men

About one million Americans carry the hepatitis B virus (HBV) which can lead to liver cancer. But the search for treatments has been stymied by the lack of a suitable animal for testing new drugs. Rodents don’t get HBV, and chimpanzees, which do, are expensive.

XTL Biopharmacueticals in Rehovot, Israel, has come up with a solution by creating a mouse with a bit of human liver inside it. XTL’s recipe: destroy the immune system of a normal mouse with gamma rays. Next, transplant a peppercorn-sized fragment of HBV-infected human liver, along with bone marrow from an immune-deficient mouse. XTL calls the resulting creature a “trimera” because it has components of three different animals. Since the mouse’s weak immune system doesn’t reject the human cells, there is time to test the effects of anti-viral drugs. XTL hopes to develop trimera models for cancer.

Keep Reading

Most Popular

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

It’s time to retire the term “user”

The proliferation of AI means we need a new word.

The problem with plug-in hybrids? Their drivers.

Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.

Sam Altman says helpful agents are poised to become AI’s killer function

Open AI’s CEO says we won’t need new hardware or lots more training data to get there.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.